Investor · 2 deals
Every published round Flu Lab took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| ENA Respiratory | Series B | 22 Oct 2025 | $34m | Participant | Startup Daily (4 Sep 2026), Startup Daily (31 Oct 2025), SmartCompany (31 Oct 2025), Startup Daily (29 Oct 2025), Startup Daily (27 Oct 2025), Brandon Capital, AFR Technology, Brandon BioCatalyst, Mirage News, SmartCompany (27 Oct 2025), enarespiratory.com, finance.yahoo.com, Brandon Capital portfolio, Stoic Venture Capital portfolio, Stoic Venture Capital portfolio | |
| ENA Respiratory | Unnamed stage | 10 Feb 2025 | US$5m (A$8m) | Lead | Brandon Capital, Brandon BioCatalyst |
Companies Flu Lab has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| ENA Respiratory | Antiviral nasal spray to prevent severe respiratory viral infections | 10 Feb 2025 | 2 | 1 |
Fund closes reported for Flu Lab, as distinct from the investments it has made.
Companies Flu Lab has backed that another company then bought. An exit for the holding, not a deal Flu Lab did.
Stories naming Flu Lab. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech ENA Respiratory has begun dosing participants in the second part of its Phase IIa trial of INNA-051; its investor lineup, past government funding awards and BLUE KNIGHT alumni status are recapped.
Melbourne-based ENA Respiratory announced US patent allowances covering its TLR2 agonist platform and a COPD treatment method, strengthening IP protection for its INNA-051 nasal spray candidate now in Phase II testing.
Melbourne biotech ENA Respiratory has begun dosing volunteers in a mid-stage trial of its INNA-051 antiviral spray, aimed at limiting common viral illnesses in at-risk groups.
Weekly funding roundup covering eight raises totalling over $113 million across aerospace, biotech, materials, health and software, plus a pharmacy firm's acquisition out of administration.
Weekly roundup of eight trans-Tasman startup raises worth a combined $113 million-plus, alongside Joe Zhou's buyout of StrongRoom AI from administrators.
A profile of ENA Respiratory traces its INNA-051 immune-boosting nasal spray from an accidental lab finding to Phase 2 trials, noting AUD 49 million in funding, a US Defence contract and Flu Lab investment.
Melbourne pharmaceutical company ENA Respiratory has received US$5 million from California's Flu Lab to advance clinical testing of its nasal immune-boosting antiviral candidate INNA-051.